Translational PK/PD/efficacy modeling and efficacious human dose prediction for a first-in-class MUC1-EGFR (M1231) bispecific antibody drug conjugate

被引：0
|
作者：
Zutshi, Anup [1 ]
Neuteboom, Berend [1 ]
Kumar, Seema [1 ]
Sloot, Willem [2 ]
Knuehl, Christine [2 ]
Dotterweich, Julia [2 ]
Ma, Jianguo [1 ]
Amendt, Christiane [2 ]
Venkatakrishnan, Karthik [1 ]
Park, Taeshin [3 ]
Pappas, John [3 ]
Kim, Kyoung-Ae [3 ]
机构：
[1] EMD Serono, Billerica, MA USA
[2] Merck KGaA, Darmstadt, Germany
[3] RES Inc, Needham, MA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5423
引用
收藏
页数：1
相关论文
共 10 条
  • [1] Preclinical studies of the bispecific MUC1xEGFR antibody drug conjugate M1231 in EGFR mutant NSCLC
    Codony-Servat, J.
    Dotterweich, J.
    Molina-Vila, M. A.
    Roman, R.
    Gimenez-Capitan, A.
    Aldeguer, E.
    Rodriguez, S.
    Knuehl, C.
    Rosell, R.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S89 - S89
  • [2] M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression.
    Knuehl, Christine
    Toleikis, Lars
    Dotterweich, Julia
    Ma, Jianguo
    Kumar, Seema
    Ross, Edith
    Wilm, Claudia
    Schmitt, Martina
    Grote, Hans Juergen
    Amendt, Christiane
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Development of a highly efficacious, first-in-class antibody-drug conjugate against a novel MUC1-C oncoprotein for metastatic colorectal cancer
    Raina, Deepak
    Panchamoorthy, Govind
    Ahmad, Rehan
    Jasuja, Ravi
    Kharbanda, Surender
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] A first-in-class bispecific antibody- drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1
    Zhang, Yifu
    Shang, Chenzhang
    Wang, Nannan
    An, Gao
    Zhang, Ellen
    Lin, Qingcong
    Yang, Yi
    CANCER RESEARCH, 2023, 83 (08)
  • [5] A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy
    Li, Zhuolin
    Shang, Chengzhang
    Guan, Xuewa
    An, Gao
    Guo, Yuming
    Zhang, Ellen
    Lin, Qingcong
    Yang, Yi
    CANCER RESEARCH, 2023, 83 (08)
  • [6] Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
    Song, Ling
    Xue, Junsheng
    Zhang, Jing
    Li, Si
    Liu, Dongyang
    Zhou, Tianyan
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 158
  • [7] BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity
    Han, Zhenyan
    Shang, Chengzhang
    Zhang, Yifu
    An, Gao
    Guo, Chaoshe
    An, W. Frank
    Yang, Yi
    CANCER RESEARCH, 2024, 84 (06)
  • [8] BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody- drug conjugate, in patients with locally advanced or metastatic solid tumours: afirst-in-human, open-label, multicentre, phase 1 study
    Ma, Yuxiang
    Huang, Yan
    Zhao, Yuanyuan
    Zhao, Shen
    Xue, Jinhui
    Yang, Yunpeng
    Fang, Wenfeng
    Guo, Ye
    Han, Yaqian
    Yang, Kunyu
    Li, Yongsheng
    Yang, Jun
    Fu, Zhenming
    Chen, Gang
    Chen, Likun
    Zhou, Ningning
    Zhou, Ting
    Zhang, Yaxiong
    Zhou, Huaqiang
    Liu, Qianwen
    Zhu, Yi
    Zhu, Hai
    Xiao, Sa
    Zhang, Li
    Zhao, Hongyun
    LANCET ONCOLOGY, 2024, 25 (07): : 901 - 911
  • [9] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study
    Zhang, Li
    Ma, Yuxiang
    Zhao, Yuanyuan
    Fang, Wenfeng
    Zhao, Hongyun
    Huang, Yan
    Yang, Yunpeng
    Chen, Likun
    Hou, Xue
    Zou, Wen
    Ding, Muran
    Yu, Jing
    Zhang, Suoyu
    Wang, Junxian
    Xiao, Sa
    Wang, Hongwei
    Zhu, Hai
    Olivo, Martin Sebastian
    Zhu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
    Zhang, L.
    Ma, Y.
    Zhao, Y.
    Fang, W. F.
    Zhao, H.
    Huang, Y.
    Yang, Y.
    Hou, X.
    Wen, Z.
    Zhang, S.
    Wang, J.
    Xiao, S.
    Wang, H.
    Zhu, H.
    Olivo, M. S.
    Zhu, Y.
    ANNALS OF ONCOLOGY, 2023, 34
1